TMO THERMO FISHER SCIENTIFIC INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$724.39

Period return

+271.79 (+60.05%)

Volume

599.6K

2026-11-11O $719.69 H $727.56 L $716.47 C $724.39MA5 $707.18MA20 $695.45MA60 $659.94MA120 $591.61

6M · 129 barsYahoo Finance · USD2026-05-11 → 2026-11-11

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 09. 26.Medium2 months ago
Q3 2026 earnings
EPS 4.64 · 매출 121.4억. 세부 수치와 가이던스는 원문에서 확인하세요.
2026. 06. 27.Medium5 months ago
Q2 2026 earnings
EPS 4.68 · 매출 119.9억. 세부 수치와 가이던스는 원문에서 확인하세요.
2026. 05. 15.High6 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.32%
2026. 05. 15.High6 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.08%
2026. 03. 28.Medium8 months ago
Q1 2026 earnings
EPS 4.43 · 매출 110.1억. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 12. 31.Medium11 months ago
Q4 2025 earnings
매출 122.2억. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 09. 27.Mediumlast year
Q3 2025 earnings
EPS 4.27 · 매출 111.2억. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 06. 28.Mediumlast year
Q2 2025 earnings
EPS 4.28 · 매출 108.6억. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 03. 29.Medium2 years ago
Q1 2025 earnings
EPS 3.98 · 매출 103.6억. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 12. 31.Medium2 years ago
Q4 2024 earnings
매출 114억. 세부 수치와 가이던스는 원문에서 확인하세요.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
FY2026 Q3	2026. 09. 26.	Time TBD	—	$4.64	—	—	$12.14B	Reported
FY2026 Q2	2026. 06. 27.	Time TBD	—	$4.68	—	—	$11.99B	Reported
FY2026 Q1	2026. 03. 28.	Time TBD	—	$4.43	—	—	$11.01B	Reported
FY2025 Q4	2025. 12. 31.	Time TBD	—	—	—	—	$12.22B	Reported

Research actions

Consensus PT $756.52 · 25 analysts

Research tab →

No research actions to show.

Key stats

As of FY2026Q3 · Source: SEC/DART + price data

Market cap$266.1B

Shares out.371M

PER40.48x

EPS (TTM)$17.74

PBR4.86x

BPS$147.80

Dividend/share—

Dividend yield—

ConsensusStrong buy

Price target$756.52+5.3%

Target range$590.00 ~ $830.00· 25 analysts

Last earnings vs est.Beat +4.3%

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	436,858	$253.14M	0.41%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	353,541	$173.78M	0.32%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	187,893	$92.36M	0.08%	—	New position
4	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	9,300	$5.39M	0.01%	—	New position

Company info

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare
Industry: Diagnostics & Research
HQ: Waltham, MA, United States
Fiscal year end: —
Employees: 125,000
IPO date: —

View details →

Top news

Stored first · Google News · Yahoo Finance (English)

Quarter

Date

Time

EPS est.

EPS actual

Surprise

Rev. est.

Rev. actual

Status

FY2026 Q3

2026. 09. 26.

Time TBD

—

$4.64

—

$12.14B

Reported

FY2026 Q2

2026. 06. 27.

Time TBD

—

$4.68

—

$11.99B

Reported

FY2026 Q1

2026. 03. 28.

Time TBD

—

$4.43

—

$11.01B

Reported

FY2025 Q4

2025. 12. 31.

Time TBD

—

$12.22B

Reported

Institution

Mandate

Value

Weight

Change

Position

Point72 Asset Management, L.P.

436,858

$253.14M

0.41%

—

New position

Point72 Asset Management, L.P.

353,541

$173.78M

0.32%

—

New position

TWO SIGMA INVESTMENTS, LP

187,893

$92.36M

0.08%

—

New position

TWO SIGMA INVESTMENTS, LP

9,300

$5.39M

0.01%

—

New position